Owlet (OWLT)
Market Price (9/19/2026): $4.72 | Market Cap: $134.6 MilSector: Health Care | Industry: Life Sciences Tools & Services
Owlet (OWLT)
Market Price (9/19/2026): $4.72Market Cap: $134.6 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Wearable Health Devices, and Remote Patient Monitoring. | Weak multi-year price returns2Y Excs Rtn is -18%, 3Y Excs Rtn is -39% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.5% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.8%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8.6% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% Key risksOWLT key risks include [1] ongoing FDA regulatory challenges and a related investor lawsuit, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Wearable Health Devices, and Remote Patient Monitoring. |
| Weak multi-year price returns2Y Excs Rtn is -18%, 3Y Excs Rtn is -39% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.5% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.8%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8.6% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| Key risksOWLT key risks include [1] ongoing FDA regulatory challenges and a related investor lawsuit, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Owlet (OWLT) stock has lost about 15% since 5/31/2026 because of the following key factors:
1. Revised Full-Year Revenue Guidance for Fiscal 2026.
Owlet, Inc. lowered its full-year fiscal 2026 revenue guidance on May 7, 2026, during its fiscal Q1 2026 earnings report (fiscal Q1 2026 ended March 31, 2026). The company adjusted its revenue expectations to a range of $118 million to $122 million, down from the previous guidance of $126 million to $130 million. This revised outlook, representing 12% to 15% growth over 2025, indicated a slower growth trajectory than initially projected, likely impacting investor sentiment as the period began.
2. Cautious Outlook for Second Half of Fiscal 2026.
Despite reporting better-than-expected fiscal Q2 2026 results on August 11, 2026, (fiscal Q2 2026 ended June 30, 2026), Owlet's management expressed a cautious tone regarding the second half of fiscal year 2026. This caution was attributed to "aggressive competitor discounting" and "limited visibility following Amazon's August 10 deadline for non-FDA-cleared vital-sign monitoring products." While the company's revenue of $33.9 million for the quarter surpassed analyst estimates of $31.71 million, and the adjusted EPS loss of -$0.01 beat the forecast of -$0.10, the forward-looking concerns weighed on the stock.
Show more
Owlet (OWLT) stock has lost about 15% since 5/31/2026 because of the following key factors:
1. Revised Full-Year Revenue Guidance for Fiscal 2026.
Owlet, Inc. lowered its full-year fiscal 2026 revenue guidance on May 7, 2026, during its fiscal Q1 2026 earnings report (fiscal Q1 2026 ended March 31, 2026). The company adjusted its revenue expectations to a range of $118 million to $122 million, down from the previous guidance of $126 million to $130 million. This revised outlook, representing 12% to 15% growth over 2025, indicated a slower growth trajectory than initially projected, likely impacting investor sentiment as the period began.
2. Cautious Outlook for Second Half of Fiscal 2026.
Despite reporting better-than-expected fiscal Q2 2026 results on August 11, 2026, (fiscal Q2 2026 ended June 30, 2026), Owlet's management expressed a cautious tone regarding the second half of fiscal year 2026. This caution was attributed to "aggressive competitor discounting" and "limited visibility following Amazon's August 10 deadline for non-FDA-cleared vital-sign monitoring products." While the company's revenue of $33.9 million for the quarter surpassed analyst estimates of $31.71 million, and the adjusted EPS loss of -$0.01 beat the forecast of -$0.10, the forward-looking concerns weighed on the stock.
3. Analyst Price Target Reductions and Downgrades.
Several analyst firms revised their outlooks for Owlet during the specified period. On June 22, 2026, TD Cowen reaffirmed a "buy" rating but lowered its price target for Owlet from $13.00 to $10.00. Later, on September 10, 2026, Weiss Ratings downgraded Owlet from a "sell (d-)" rating to a "sell (e+)" rating. These adjustments signal reduced confidence in the stock's future performance.
4. Bearish Technical Indicator Crossovers.
The stock experienced several bearish technical signals in August 2026, contributing to its downward trend. The Moving Average Convergence Divergence Histogram (MACD) turned negative on August 21, 2026. On the same date, Owlet's stock moved below its 50-day moving average, signaling a shift from an upward to a downward trend. Furthermore, the 10-day moving average crossed below the 50-day moving average on August 28, 2026, reinforcing the negative technical outlook.
Show less
Stock Movement Drivers
Fundamental Drivers
The -14.3% change in OWLT stock from 5/31/2026 to 9/18/2026 was primarily driven by a -16.9% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.53 | 4.74 | -14.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 107 | 115 | 7.3% |
| P/S Multiple | 1.4 | 1.2 | -16.9% |
| Shares Outstanding (Mil) | 27 | 29 | -3.9% |
| Cumulative Contribution | -14.3% |
Market Drivers
5/31/2026 to 9/18/2026| Return | Correlation | |
|---|---|---|
| OWLT | -14.3% | |
| Market (SPY) | 0.9% | 33.5% |
| Sector (XLV) | 12.7% | -10.6% |
Fundamental Drivers
The -59.0% change in OWLT stock from 2/28/2026 to 9/18/2026 was primarily driven by a -43.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.55 | 4.74 | -59.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 100 | 115 | 15.3% |
| P/S Multiple | 1.9 | 1.2 | -37.3% |
| Shares Outstanding (Mil) | 16 | 29 | -43.2% |
| Cumulative Contribution | -59.0% |
Market Drivers
2/28/2026 to 9/18/2026| Return | Correlation | |
|---|---|---|
| OWLT | -59.0% | |
| Market (SPY) | 11.6% | 40.9% |
| Sector (XLV) | 5.5% | 7.7% |
Fundamental Drivers
The -37.1% change in OWLT stock from 8/31/2025 to 9/18/2026 was primarily driven by a -44.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.53 | 4.74 | -37.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 90 | 115 | 27.9% |
| P/S Multiple | 1.3 | 1.2 | -10.7% |
| Shares Outstanding (Mil) | 16 | 29 | -44.9% |
| Cumulative Contribution | -37.1% |
Market Drivers
8/31/2025 to 9/18/2026| Return | Correlation | |
|---|---|---|
| OWLT | -37.1% | |
| Market (SPY) | 19.4% | 35.0% |
| Sector (XLV) | 24.1% | 3.8% |
Fundamental Drivers
The 54.4% change in OWLT stock from 8/31/2023 to 9/18/2026 was primarily driven by a 148.0% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.07 | 4.74 | 54.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 115 | 116.2% |
| P/S Multiple | 0.5 | 1.2 | 148.0% |
| Shares Outstanding (Mil) | 8 | 29 | -71.2% |
| Cumulative Contribution | 54.4% |
Market Drivers
8/31/2023 to 9/18/2026| Return | Correlation | |
|---|---|---|
| OWLT | 54.4% | |
| Market (SPY) | 75.6% | 25.1% |
| Sector (XLV) | 32.3% | 12.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OWLT Return | -74% | -79% | -33% | -16% | 264% | -72% | -97% |
| Peers Return | 35% | -67% | 171% | 18% | 25% | -5% | 71% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| OWLT Win Rate | 33% | 33% | 42% | 50% | 83% | 22% | |
| Peers Win Rate | 67% | 25% | 83% | 50% | 50% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| OWLT Max Drawdown | -76% | -89% | -69% | -51% | -46% | -73% | |
| Peers Max Drawdown | -45% | -72% | -31% | -41% | -42% | -21% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARLO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | OWLT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -44.0% | -18.8% |
| % Gain to Breakeven | 78.6% | 23.1% |
| Time to Breakeven | 38 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -37.3% | -9.5% |
| % Gain to Breakeven | 59.6% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -40.9% | -6.7% |
| % Gain to Breakeven | 69.2% | 7.1% |
| Time to Breakeven | 13 days | 31 days |
In The Past
Owlet's stock fell -44.0% during the 2025 US Tariff Shock. Such a loss loss requires a 78.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OWLT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -44.0% | -18.8% |
| % Gain to Breakeven | 78.6% | 23.1% |
| Time to Breakeven | 38 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -37.3% | -9.5% |
| % Gain to Breakeven | 59.6% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -40.9% | -6.7% |
| % Gain to Breakeven | 69.2% | 7.1% |
| Time to Breakeven | 13 days | 31 days |
In The Past
Owlet's stock fell -44.0% during the 2025 US Tariff Shock. Such a loss loss requires a 78.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Owlet (OWLT)
Owlet, Inc. (OWLT) operates as a digital parenting platform primarily focused on providing parents with real-time data and insights into their infants' health and well-being. The company's mission is to offer innovative technological solutions that bring peace of mind and support to families during the early stages of parenthood.
The company's core product offerings revolve around monitoring and sleep assistance. Key products include the Smart Sock, a wearable baby monitor that tracks vital signs such as oxygen levels, heart rates, and sleep trends. Complementing this, the Dream Sock is an app designed to assist children in achieving better sleep, while Dream Lab is an interactive online platform dedicated to helping families establish healthy sleep habits. For visual monitoring, Owlet offers the Cam, a video streaming app enabling parents to see and hear their baby from anywhere. The Dream Duo combines these functionalities into a comprehensive monitoring system, featuring a wearable sock monitor, HD video, and a digital sleep coach.
Owlet primarily serves parents and families in the United States. Its market consists of new parents and those with infants who are looking for advanced monitoring solutions to track their baby's health metrics, understand sleep patterns, and receive guidance on developing healthy sleep routines. By combining wearable technology with digital support and monitoring, Owlet aims to empower its customers with data-driven tools for proactive and informed childcare.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Owlet:
Fitbit for babies: It tracks an infant's oxygen levels, heart rate, and sleep trends.
Google Nest for the nursery: It offers a suite of smart monitoring devices, including cameras and smart socks, for the baby's room.
Headspace for infant sleep: It provides digital tools and coaching to help families establish healthy sleep habits for their children.
AI Analysis | Feedback
- Smart Sock: A baby monitor designed to track an infant's oxygen levels, heart rates, and sleep trends.
- Dream Sock: An app designed to assist children for better sleep.
- Cam: A video streaming app that allows parents to hear and see their baby from anywhere.
- Dream Lab: An interactive online platform that assists families in building healthy sleep habits.
- Dream Duo: A comprehensive monitoring system for a baby's sleeping habits, which includes a wearable sock monitor, HD video, and a digital sleep coach.
AI Analysis | Feedback
Owlet (OWLT) primarily sells its products directly to individuals.
Customer Categories:
- New and Expecting Parents: Individuals preparing for or having recently welcomed an infant, seeking tools for monitoring their baby's health (oxygen levels, heart rate), sleep patterns, and overall well-being. This group is interested in products like the Smart Sock and Cam for basic monitoring and reassurance.
- Parents Seeking Sleep Solutions for Infants and Young Children: Families looking for assistance and guidance to establish healthy sleep habits for their babies and young children. This category benefits from products like the Dream Sock, Dream Lab, and Dream Duo, which focus on improving sleep routines and providing sleep coaching.
- Health-Conscious and Tech-Savvy Parents: Individuals who value real-time data and insights into their child's vital signs and sleep trends, using technology to gain peace of mind and proactively manage their child's health and development. They appreciate the detailed information provided by Owlet's integrated platform.
AI Analysis | Feedback
- Shenzhen Huitongda Electronics Co., Ltd.
- Shenzhen Innoful Technology Co., Ltd.
AI Analysis | Feedback
Jonathan Harris, President & Chief Executive Officer
Jonathan Harris was appointed President and Chief Executive Officer of Owlet, Inc. effective October 1, 2025. He brings over 30 years of experience in management and advisory roles in hardware and software companies. Prior to joining Owlet, he held leadership positions, including Chief Executive Officer, at Molekule Group, Inc. (formerly AeroClean Technologies, Inc.), an air purification technology company, where he was involved in restructuring and a merger. Mr. Harris also served as Chief Executive Officer and Co-Founder of KAMU Labs, Inc. He is noted for scaling GoPro from $19 million to over $1.5 billion in revenue globally and contributing to the company's initial public offering (IPO). Additionally, he was a founder of FiftyThree, Inc. His career includes work with brands such as Jawbone, Roku, and Microsoft.
Amanda Twede Crawford, Chief Financial Officer
Amanda Twede Crawford became the Chief Financial Officer of Owlet, Inc. on July 9, 2024. She has over 15 years of extensive experience in accounting and finance. Before her appointment as CFO, Ms. Crawford served as Owlet's Vice President of Financial Planning and Analysis for two years. Previously, she held key leadership roles at Swire Coca-Cola, USA, including Vice President of Finance and Corporate Controller, where she contributed to scaling the business from $500 million to over $2.5 billion through strategic acquisitions and organic growth. She began her career at PricewaterhouseCoopers and is a Certified Public Accountant.
Kurt Workman, Executive Chairman and Co-Founder
Kurt Workman co-founded Owlet in 2012 and transitioned from Chief Executive Officer to Executive Chairman of the Board of Directors on October 1, 2025. He was instrumental in leading the company's growth and strategy from its inception and oversaw the research and development of key products, including the Owlet Dream Sock. Mr. Workman has an entrepreneurial background, having started a paintball company at 13 and a tiling business during college. He also mentors young entrepreneurs and runs an incubator program in Mexico.
Burc Sahinoglu, Chief Technology Officer
Burc Sahinoglu serves as the Chief Technology Officer at Owlet, where he is responsible for leading all hardware and software engineering efforts for current and future products and services. He possesses three decades of experience encompassing startup management, research and development, and cloud computing. Before joining Owlet, Mr. Sahinoglu was part of the engineering leadership team at August Home, from its Series A funding through its acquisition by ASSA ABLOY in 2017.
David Kizer, Chief Operating Officer
David Kizer is the Chief Operating Officer at Owlet, overseeing all aspects of manufacturing, supply chain, sourcing, IT, and customer service. He has over a decade of experience in launching and scaling businesses. Prior to his role at Owlet, Mr. Kizer served as a product director at Gioteck and held various positions at Skullcandy.
AI Analysis | Feedback
1. Regulatory Challenges and Compliance (FDA)
Owlet operates in a highly regulated environment, particularly concerning its core product, the Smart Sock, which the U.S. Food and Drug Administration (FDA) has classified as a medical device. Historically, Owlet faced a warning letter from the FDA in 2021, asserting that the Smart Sock was being marketed without proper clearance or approval, leading the company to halt sales of the product. While Owlet successfully reintroduced its Dream Sock with FDA clearance as the first over-the-counter infant monitoring device, the need for continuous regulatory approval for new products, ongoing scrutiny of its existing offerings, and potential foreign regulatory hurdles pose significant risks to its operations and product development pipeline.2. Financial Stability and Capital Needs
Despite recent revenue growth and achieving positive Adjusted EBITDA, Owlet has a history of net losses and is considered a "going concern" with inherent liquidity risks. The company may require additional capital to fund its extensive growth plans and operations, which could lead to further dilution for shareholders. Material weaknesses in internal controls over financial reporting have also been identified, raising concerns about financial stability and potentially affecting access to capital markets. The company's balance sheet has shown a negative equity position and a distressing Altman Z-Score, indicating a potential risk of bankruptcy.3. Intense Market Competition and Demographic Headwinds
Owlet faces ongoing competition in the smart baby monitoring market. While its FDA-cleared Dream Sock provides a competitive advantage and a "moat," new competitors or technological advancements could impact its pricing power and market share. Additionally, a macro headwind for the company's growth is the declining birth rates in the United States and Western societies, which could limit its potential customer base.AI Analysis | Feedback
Advances in non-contact infant monitoring technologies. The core of Owlet's business, particularly the Smart Sock and Dream Sock, relies on wearable technology to track vital signs and sleep patterns. Emerging technologies, such as advanced computer vision, radar, and other remote sensing methods, are increasingly capable of accurately monitoring physiological data (like breathing, heart rate, and movement indicative of sleep stages) without requiring a physical device to be worn by the infant. Should these non-contact solutions become more accurate, reliable, affordable, and widely adopted, they could significantly undermine the value proposition of Owlet's wearable products, potentially making them seem intrusive or unnecessary.
AI Analysis | Feedback
Addressable Markets for Owlet's Main Products and Services
Owlet, Inc. operates within several interconnected addressable markets related to digital parenting and infant care technology.
Smart Sock and Dream Sock (Wearable Smart Baby Monitors / Infant Sleep Trackers)
- The global wearable smart baby monitor market was estimated at approximately USD 2.44 billion in 2025 and is predicted to increase to about USD 4.60 billion by 2035, with a compound annual growth rate (CAGR) of 6.55% from 2026 to 2035.
- The global sleep trackers market was valued at USD 26.60 billion in 2024 and is expected to reach USD 47.79 billion by 2032, growing at a CAGR of 7.6% during that period.
- The North American sleep trackers market was valued at USD 2.02 billion in 2025.
Cam and Dream Duo (Smart Baby Monitors with Video and Audio)
- The global smart baby monitor market size was valued at USD 1.85 billion in 2025 and is projected to grow at a CAGR of 8.25% to reach USD 4.09 billion by 2035.
- The U.S. smart baby monitor market size was valued at USD 0.51 billion in 2025 and is projected to reach USD 0.80 billion by 2035, growing at a CAGR of 5.64% from 2026 to 2035.
Dream Lab (Digital Parenting Platform / Parenting Apps / Online Parenting Education)
- The global parenting apps market was valued at approximately USD 1.72 billion in 2025 and is predicted to reach USD 4.91 billion by 2035, at an 11.40% CAGR.
- The North America parenting apps market is expected to reach US$ 355.74 million by 2028.
- The global online parenting education market size was approximately USD 954.87 million in 2025 and is projected to reach USD 2275.60 million by 2034, growing at a CAGR of 10.13% from 2025 to 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Owlet (symbol: OWLT) over the next 2-3 years:
- Global Expansion and Dream Sock Adoption: Owlet is focused on driving the global adoption of its Dream Sock and other products. The company has secured regulatory clearances for Dream Sock sales in new international markets, including India and Israel, with further expansion planned for regions like Europe (Poland, Greece, Czech Republic) and South Africa. This international footprint aims to broaden Owlet's customer base significantly.
- Expansion of the Owlet360 Subscription Platform: The Owlet360 subscription service is a key driver for recurring revenue. The platform has seen significant growth in paying subscribers, surpassing 110,000 by the end of 2025. Owlet plans to continue expanding this platform, including its international availability, by offering personalized guidance, expert resources, and enhanced analytics to increase customer lifetime value.
- Growth in Healthcare Channels with BabySat: Owlet is actively expanding its presence in healthcare channels, particularly with its FDA-cleared prescription pulse oximeter, BabySat. Strategic partnerships with Durable Medical Equipment (DME) providers, such as PromptCare, are designed to broaden access to BabySat through established pediatric care pathways. The company is also working to increase insurance reimbursement coverage for its medical devices.
- Launch of the Owlet OnCall Telehealth Platform: Owlet plans to launch its Owlet OnCall Telehealth Platform in the first half of 2026. This new service is expected to leverage the data and insights from Dream Sock and Owlet360 to capitalize on the growing telehealth market, offering new revenue streams and enhancing integrated care for families.
- Integration of AI-Driven Features and Product Innovation: Owlet is leveraging artificial intelligence (AI) to drive product innovation and enhance customer retention. Features like the Dream Sight camera with onboard AI, introduced in September 2025, and AI Sleep Insight are designed to provide actionable daily plans for parents, thereby increasing the value and stickiness of Owlet's ecosystem.
AI Analysis | Feedback
Share Repurchases
- Owlet did not repurchase shares of its common stock during the three months ended December 31, 2025.
Share Issuance
- In October 2025, Owlet issued 5,426,429 shares through a warrant exchange to simplify its capital structure.
- In October 2025, the company completed a public offering of 4,196,000 shares of Class A common stock at $7.15 per share, raising approximately $30.0 million in gross proceeds.
- The net proceeds from the October 2025 public offering were intended to support continued commercialization, research and development, and for general corporate purposes.
Capital Expenditures
- Owlet's capital expenditures for the last 12 months (covering much of 2025) were approximately $273,000.
Peer Outperformance in Life Sciences Tools & Services
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| OWLT | Owlet | 29.4% | -15.0x | -42.1% | 25.4% | -93.8% | — |
| GH | Guardant Health | 32.6% | -52.6x | 205.1% | 550.2% | 35.8% | +130pp |
| WGS | GeneDx | 25.7% | -28.2x | -22.7% | 2459.5% | -67.4% | +26pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 15.4% | 45.5% | 86.6% | CAH 378% · MCK 331% · COR 164% |
| Managed Health Care | 8 | 39.0% | -2.8% | 0.1% | OSCR 84% · HQY 49% · ELV 16% |
| Health Care Services | 20 | 20.1% | 39.2% | -1.3% | HIMS 221% · RDNT 166% · DGX 75% |
| Health Care Facilities | 24 | 4.2% | 3.1% | -13.4% | NHC 269% · THC 259% · ENSG 125% |
| Health Care Equipment | 50 | -3.2% | -5.0% | -22.6% | POCI 11050% · UFPT 336% · GKOS 204% |
| Pharmaceuticals | 62 | -8.2% | 11.7% | -40.1% | LQDA 2386% · INDV 1146% · ETON 982% |
| Health Care Supplies | 12 | 13.1% | -12.7% | -40.8% | LNTH 293% · HAE 54% · MMSI 19% |
| Life Sciences Tools & Services ← | 109 | 5.2% | -17.4% | -68.8% | SNWV 1757% · MEDP 229% · NTRA 192% |
| Biotechnology | 364 | -0.7% | -25.7% | -79.5% | CELZ 1280% · DNTH 1143% · ELVN 1058% |
| Health Care Technology | 21 | -23.7% | -51.7% | -79.9% | SPOK 72% · HSTM 2% · VEEV -14% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Owlet Earnings Notes | 12/16/2025 | |
| With Owlet Stock Climbed 15% In A Month, How Confident Are You? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.99 |
| Mkt Cap | 0.8 |
| Rev LTM | 351 |
| Op Inc LTM | 4 |
| FCF LTM | 29 |
| FCF 3Y Avg | 21 |
| CFO LTM | 35 |
| CFO 3Y Avg | 25 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 21.8% |
| Rev Chg 3Y Avg | 18.6% |
| Rev Chg Q | 25.2% |
| QoQ Delta Rev Chg LTM | 6.0% |
| Op Inc Chg LTM | 148.5% |
| Op Inc Chg 3Y Avg | 82.0% |
| Op Mgn LTM | -1.9% |
| Op Mgn 3Y Avg | -9.7% |
| QoQ Delta Op Mgn LTM | 1.8% |
| CFO/Rev LTM | 3.3% |
| CFO/Rev 3Y Avg | -1.2% |
| FCF/Rev LTM | 1.4% |
| FCF/Rev 3Y Avg | -2.3% |
Price Behavior
| Market Price | $4.74 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/05/2020 | |
| Distance from 52W High | -71.3% | |
| 50 Days | 200 Days | |
| DMA Price | $5.35 | $7.89 |
| DMA Trend | down | indeterminate |
| Distance from DMA | -11.4% | -39.9% |
| 3M | 1YR | |
| Volatility | 59.4% | 81.6% |
| Downside Capture | 139.04 | 279.67 |
| Upside Capture | 96.19 | 168.28 |
| Correlation (SPY) | 29.7% | 35.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.12 | 1.95 | 1.56 | 2.62 | 2.22 | 1.28 |
| Up Beta | 0.69 | 1.92 | 1.82 | 3.07 | 2.75 | 0.76 |
| Down Beta | 8.61 | 0.74 | 1.67 | 2.75 | 1.96 | 1.47 |
| Up Capture | 154% | 122% | 116% | 134% | 238% | 387% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 8 | 14 | 27 | 49 | 112 | 352 |
| Down Capture | 329% | 322% | 163% | 248% | 172% | 110% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 13 | 27 | 35 | 74 | 133 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OWLT | |
|---|---|---|---|---|
| OWLT | -36.7% | 82.0% | -0.17 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 3.2% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 35.6% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 11.7% |
| Commodities (DBC) | 46.9% | 20.6% | 1.76 | -17.3% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 11.6% |
| Bitcoin (BTCUSD) | -34.5% | 43.9% | -0.84 | 21.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OWLT | |
|---|---|---|---|---|
| OWLT | -44.1% | 89.6% | -0.24 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 15.7% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 24.2% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 6.1% |
| Commodities (DBC) | 11.3% | 19.5% | 0.45 | -0.3% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 13.7% |
| Bitcoin (BTCUSD) | 11.2% | 52.5% | 0.39 | 12.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OWLT | |
|---|---|---|---|---|
| OWLT | -28.8% | 84.8% | -0.30 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 14.9% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 22.7% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 5.5% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | -0.7% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 12.8% |
| Bitcoin (BTCUSD) | 61.7% | 66.1% | 1.02 | 10.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 6.8% | 7.5% | -13.8% |
| 5/7/2026 | 18.1% | 11.1% | -1.4% |
| 3/5/2026 | -38.2% | -54.0% | -56.6% |
| 11/13/2025 | 3.1% | 17.7% | 25.2% |
| 8/7/2025 | 19.1% | -1.3% | -10.0% |
| 5/8/2025 | 16.1% | 28.1% | 47.5% |
| 3/4/2025 | 9.3% | -2.4% | -14.7% |
| 11/13/2024 | -10.5% | -17.6% | -7.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 6 | 4 |
| # Negative | 9 | 13 | 15 |
| Median Positive | 7.2% | 10.7% | 36.3% |
| Median Negative | -7.9% | -10.1% | -22.5% |
| Max Positive | 19.1% | 28.1% | 88.3% |
| Max Negative | -38.2% | -54.0% | -56.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 6.8% | 7.5% | -13.8% |
| 5/7/2026 | 18.1% | 11.1% | -1.4% |
| 3/5/2026 | -38.2% | -54.0% | -56.6% |
| 11/13/2025 | 3.1% | 17.7% | 25.2% |
| 8/7/2025 | 19.1% | -1.3% | -10.0% |
| 5/8/2025 | 16.1% | 28.1% | 47.5% |
| 3/4/2025 | 9.3% | -2.4% | -14.7% |
| 11/13/2024 | -10.5% | -17.6% | -7.9% |
| 8/12/2024 | 7.7% | -2.8% | -7.1% |
| 5/6/2024 | -7.9% | -10.1% | 7.9% |
| 3/7/2024 | -10.0% | -24.3% | -31.3% |
| 11/13/2023 | -7.6% | -7.8% | -22.5% |
| 5/11/2023 | -0.7% | -16.7% | -35.1% |
| 3/15/2023 | 6.1% | 10.3% | -8.2% |
| 11/14/2022 | -7.9% | -28.6% | -36.7% |
| 8/11/2022 | 0.0% | 10.3% | -23.4% |
| 3/7/2022 | -10.9% | -7.7% | 88.3% |
| 11/16/2021 | -0.7% | -13.5% | -33.2% |
| 8/12/2021 | 2.4% | -1.8% | -44.5% |
| SUMMARY STATS | |||
| # Positive | 10 | 6 | 4 |
| # Negative | 9 | 13 | 15 |
| Median Positive | 7.2% | 10.7% | 36.3% |
| Median Negative | -7.9% | -10.1% | -22.5% |
| Max Positive | 19.1% | 28.1% | 88.3% |
| Max Negative | -38.2% | -54.0% | -56.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/11/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 04/06/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/11/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 04/06/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/25/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
Recent Forward Guidance
Updated 8/12/2026Latest: Q2 2026 Earnings Reported 8/11/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 118.00 Mil | 120.00 Mil | 122.00 Mil | 0 | Affirmed | Guidance: 120.00 Mil for 2026 | |
| 2026 Gross Profit | Calculated | 62.54 Mil | 64.80 Mil | 67.10 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 53.0% | 54.0% | 55.0% | 3.0% | Raised | Guidance: 51.0% for 2026 | |
| 2026 Adjusted EBITDA | Reported | 10.75 Mil | 11.75 Mil | 12.75 Mil | 46.9% | Raised | Guidance: 8.00 Mil for 2026 | |
Prior: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 118.00 Mil | 120.00 Mil | 122.00 Mil | -6.2% | Lowered | Guidance: 128.00 Mil for 2026 | |
| 2026 Gross Profit | Calculated | 59.00 Mil | 61.20 Mil | 63.44 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 50.0% | 51.0% | 52.0% | 0.5% | Raised | Guidance: 50.5% for 2026 | |
| 2026 Adjusted EBITDA | Reported | 7.00 Mil | 8.00 Mil | 9.00 Mil | 100.0% | Raised | Guidance: 4.00 Mil for 2026 | |
Q4 2025 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 20.00 Mil | 20.50 Mil | 21.00 Mil | ||||
| Q1 2026 Gross Profit | Calculated | 10.00 Mil | 10.46 Mil | 10.92 Mil | Rev x Gross Margin | |||
| Q1 2026 Gross Margin | Reported | 50.0% | 51.0% | 52.0% | ||||
| Q1 2026 Adjusted EBITDA | Reported | -2.50 Mil | -2.00 Mil | -1.50 Mil | ||||
| 2026 Revenue | Reported | 126.00 Mil | 128.00 Mil | 130.00 Mil | 22.5% | Higher New | Actual: 104.50 Mil for 2025 | |
| 2026 Revenue Growth | Reported | 19.0% | 21.0% | 23.0% | -13.0% | Lower New | Actual: 34.0% for 2025 | |
| 2026 Gross Profit | Calculated | 61.74 Mil | 64.64 Mil | 67.60 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 49.0% | 50.5% | 52.0% | 1.5% | Higher New | Actual: 49.0% for 2025 | |
| 2026 Adjusted EBITDA | Reported | 3.00 Mil | 4.00 Mil | 5.00 Mil | 146.2% | Higher New | Actual: 1.62 Mil for 2025 | |
Q3 2025 Earnings Reported 11/13/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | Reported | 103.00 Mil | 104.50 Mil | 106.00 Mil | 6.1% | Raised | Guidance: 98.50 Mil for 2025 | |
| 2025 Revenue Growth | Reported | 32.0% | 34.0% | 36.0% | 8.0% | Raised | Guidance: 26.0% for 2025 | |
| 2025 Gross Profit | Calculated | 49.44 Mil | 51.20 Mil | 53.00 Mil | Rev x Gross Margin | |||
| 2025 Gross Margin | Reported | 48.0% | 49.0% | 50.0% | 1.0% | Raised | Guidance: 48.0% for 2025 | |
| 2025 Adjusted EBITDA | Reported | 1.25 Mil | 1.62 Mil | 2.00 Mil | ||||
Insider Activity
Updated 8/21/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 11.50 | 6,892 | 79,258 | 2,447,200 | Form |
| 2 | Harris, Jonathan | Direct | Sell | 4302026 | 11.50 | 12,676 | 145,774 | 3,902,364 | Form | |
| 3 | Harris, Jonathan | Direct | Sell | 4302026 | 10.65 | 3,540 | 37,701 | 3,305,185 | Form | |
| 4 | Harris, Jonathan | Direct | Sell | 4302026 | 10.49 | 3,423 | 35,907 | 3,292,664 | Form | |
| 5 | Harris, Jonathan | Direct | Sell | 4302026 | 8.75 | 1,851 | 16,196 | 2,776,454 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 11.50 | 6,892 | 79,258 | 2,447,200 | Form |
| 2 | Harris, Jonathan | Direct | Sell | 4302026 | 11.50 | 12,676 | 145,774 | 3,902,364 | Form | |
| 3 | Harris, Jonathan | Direct | Sell | 4302026 | 10.65 | 3,540 | 37,701 | 3,305,185 | Form | |
| 4 | Harris, Jonathan | Direct | Sell | 4302026 | 10.49 | 3,423 | 35,907 | 3,292,664 | Form | |
| 5 | Harris, Jonathan | Direct | Sell | 4302026 | 8.75 | 1,851 | 16,196 | 2,776,454 | Form | |
| 6 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 8.75 | 149 | 1,304 | 1,740,016 | Form |
| 7 | Workman, Kurt | President & CEO | Direct | Sell | 4302026 | 8.46 | 49,056 | 415,014 | 3,232,397 | Form |
| 8 | Workman, Kurt | President & CEO | Direct | Sell | 4302026 | 7.25 | 1,014 | 7,352 | 3,023,526 | Form |
| 9 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 7.06 | 4,225 | 29,828 | 1,065,982 | Form |
| 10 | Harris, Jonathan | Direct | Sell | 4302026 | 7.72 | 3,315 | 25,592 | 2,000,530 | Form | |
| 11 | Harris, Jonathan | Direct | Sell | 4302026 | 8.03 | 1,945 | 15,618 | 2,107,482 | Form | |
| 12 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 8.03 | 157 | 1,261 | 1,246,368 | Form |
| 13 | Workman, Kurt | President & CEO | Direct | Sell | 4302026 | 6.88 | 1,119 | 7,699 | 2,876,198 | Form |
| 14 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 3.20 | 142 | 454 | 497,187 | Form |
| 15 | Workman, Kurt | President & CEO | Direct | Sell | 4302026 | 4.26 | 1,044 | 4,447 | 1,785,668 | Form |
| 16 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 4302026 | 4.92 | 140 | 689 | 765,124 | Form |
| 17 | Crawford, Amanda | Chief Financial Officer | Direct | Sell | 1222026 | 13.33 | 183 | 2,439 | 2,003,832 | Form |
| 18 | Harris, Jonathan | President and CEO | Direct | Sell | 1222026 | 13.33 | 2,311 | 30,806 | 3,524,399 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.